![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: YBX1 |
Gene summary for YBX1 |
![]() |
Gene information | Species | Human | Gene symbol | YBX1 | Gene ID | 4904 |
Gene name | Y-box binding protein 1 | |
Gene Alias | BP-8 | |
Cytomap | 1p34.2 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P67809 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4904 | YBX1 | S027 | Human | Liver | HCC | 1.47e-26 | 4.20e+00 | 0.2446 |
4904 | YBX1 | S028 | Human | Liver | HCC | 1.00e-38 | 4.38e+00 | 0.2503 |
4904 | YBX1 | S029 | Human | Liver | HCC | 2.33e-41 | 4.86e+00 | 0.2581 |
4904 | YBX1 | C04 | Human | Oral cavity | OSCC | 1.15e-48 | 4.37e+00 | 0.2633 |
4904 | YBX1 | C21 | Human | Oral cavity | OSCC | 5.99e-57 | 4.68e+00 | 0.2678 |
4904 | YBX1 | C30 | Human | Oral cavity | OSCC | 5.58e-77 | 5.06e+00 | 0.3055 |
4904 | YBX1 | C38 | Human | Oral cavity | OSCC | 3.59e-41 | 2.72e+00 | 0.172 |
4904 | YBX1 | C43 | Human | Oral cavity | OSCC | 2.84e-102 | 3.26e+00 | 0.1704 |
4904 | YBX1 | C46 | Human | Oral cavity | OSCC | 6.59e-66 | 2.53e+00 | 0.1673 |
4904 | YBX1 | C51 | Human | Oral cavity | OSCC | 3.39e-36 | 3.43e+00 | 0.2674 |
4904 | YBX1 | C57 | Human | Oral cavity | OSCC | 2.95e-26 | 2.48e+00 | 0.1679 |
4904 | YBX1 | C06 | Human | Oral cavity | OSCC | 3.92e-40 | 3.91e+00 | 0.2699 |
4904 | YBX1 | C07 | Human | Oral cavity | OSCC | 4.54e-25 | 4.14e+00 | 0.2491 |
4904 | YBX1 | C08 | Human | Oral cavity | OSCC | 5.67e-46 | 2.57e+00 | 0.1919 |
4904 | YBX1 | C86 | Human | Oral cavity | OSCC | 2.87e-11 | 1.37e+00 | 0.161 |
4904 | YBX1 | C09 | Human | Oral cavity | OSCC | 1.19e-35 | 1.86e+00 | 0.1431 |
4904 | YBX1 | LN22 | Human | Oral cavity | OSCC | 7.52e-54 | 3.45e+00 | 0.1733 |
4904 | YBX1 | LN38 | Human | Oral cavity | OSCC | 1.23e-41 | 1.84e+00 | 0.168 |
4904 | YBX1 | LN46 | Human | Oral cavity | OSCC | 1.93e-38 | 2.39e+00 | 0.1666 |
4904 | YBX1 | LP15 | Human | Oral cavity | LP | 4.75e-40 | 3.49e+00 | 0.2174 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:19033118 | Breast | Precancer | regulation of mRNA metabolic process | 38/1080 | 288/18723 | 1.63e-06 | 5.97e-05 | 38 |
GO:00075688 | Breast | Precancer | aging | 41/1080 | 339/18723 | 5.95e-06 | 1.71e-04 | 41 |
GO:00313309 | Breast | Precancer | negative regulation of cellular catabolic process | 34/1080 | 262/18723 | 8.16e-06 | 2.20e-04 | 34 |
GO:00064028 | Breast | Precancer | mRNA catabolic process | 31/1080 | 232/18723 | 1.12e-05 | 2.93e-04 | 31 |
GO:00064018 | Breast | Precancer | RNA catabolic process | 34/1080 | 278/18723 | 2.88e-05 | 6.39e-04 | 34 |
GO:19033129 | Breast | Precancer | negative regulation of mRNA metabolic process | 16/1080 | 92/18723 | 6.70e-05 | 1.35e-03 | 16 |
GO:00098959 | Breast | Precancer | negative regulation of catabolic process | 36/1080 | 320/18723 | 9.92e-05 | 1.83e-03 | 36 |
GO:00346558 | Breast | Precancer | nucleobase-containing compound catabolic process | 42/1080 | 407/18723 | 1.91e-04 | 3.06e-03 | 42 |
GO:00085445 | Breast | Precancer | epidermis development | 35/1080 | 324/18723 | 2.71e-04 | 3.96e-03 | 35 |
GO:00467007 | Breast | Precancer | heterocycle catabolic process | 44/1080 | 445/18723 | 3.49e-04 | 4.88e-03 | 44 |
GO:00442708 | Breast | Precancer | cellular nitrogen compound catabolic process | 44/1080 | 451/18723 | 4.64e-04 | 6.12e-03 | 44 |
GO:00194397 | Breast | Precancer | aromatic compound catabolic process | 44/1080 | 467/18723 | 9.55e-04 | 1.07e-02 | 44 |
GO:00987608 | Breast | Precancer | response to interleukin-7 | 5/1080 | 15/18723 | 1.17e-03 | 1.26e-02 | 5 |
GO:00987618 | Breast | Precancer | cellular response to interleukin-7 | 5/1080 | 15/18723 | 1.17e-03 | 1.26e-02 | 5 |
GO:00064039 | Breast | Precancer | RNA localization | 23/1080 | 201/18723 | 1.34e-03 | 1.41e-02 | 23 |
GO:00075694 | Breast | Precancer | cell aging | 17/1080 | 132/18723 | 1.55e-03 | 1.59e-02 | 17 |
GO:19013617 | Breast | Precancer | organic cyclic compound catabolic process | 45/1080 | 495/18723 | 1.73e-03 | 1.74e-02 | 45 |
GO:00434888 | Breast | Precancer | regulation of mRNA stability | 19/1080 | 158/18723 | 1.92e-03 | 1.86e-02 | 19 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YBX1 | SNV | Missense_Mutation | c.797A>G | p.Asn266Ser | p.N266S | P67809 | protein_coding | tolerated(0.06) | possibly_damaging(0.824) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD | |
YBX1 | SNV | Missense_Mutation | c.269N>T | p.Ala90Val | p.A90V | P67809 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
YBX1 | SNV | Missense_Mutation | c.725G>C | p.Arg242Thr | p.R242T | P67809 | protein_coding | deleterious(0.01) | benign(0.351) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
YBX1 | SNV | Missense_Mutation | rs780773403 | c.611N>A | p.Arg204His | p.R204H | P67809 | protein_coding | tolerated(0.26) | benign(0.011) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
YBX1 | SNV | Missense_Mutation | novel | c.193T>G | p.Trp65Gly | p.W65G | P67809 | protein_coding | deleterious(0) | benign(0.096) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
YBX1 | SNV | Missense_Mutation | rs141968223 | c.938C>T | p.Ser313Leu | p.S313L | P67809 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
YBX1 | SNV | Missense_Mutation | c.872N>A | p.Arg291His | p.R291H | P67809 | protein_coding | tolerated(0.22) | benign(0) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
YBX1 | SNV | Missense_Mutation | novel | c.610N>T | p.Arg204Cys | p.R204C | P67809 | protein_coding | tolerated(0.19) | possibly_damaging(0.898) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
YBX1 | SNV | Missense_Mutation | rs141968223 | c.938N>T | p.Ser313Leu | p.S313L | P67809 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
YBX1 | SNV | Missense_Mutation | c.758N>C | p.Arg253Thr | p.R253T | P67809 | protein_coding | deleterious(0.04) | probably_damaging(0.987) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |